Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.

Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study Product) Evaluating the Efficacy of Respicure® 0.38% /0.38% (Resveratrol / Quercetin) Phytotherapy Product From BEKER Laboratories as an add-on Treatment in the Management of Respiratory Conditions Including Asthma (Partially Controlled),COPD (Stage A, B, C and D) and long COVID in Algerian Adult Patients .

Inclusion Criteria for Asthma patients:Male, female, aged ≥19.Being able to provide written informed consent before the study.Patient with partially controlled asthma: Assessment of asthma control over the month preceding the use of Respicure ® by a symptomatic assessment (Tick one or two symptoms):3. 1 Daytime symptoms more than twice a week, 3. 2 One or more nocturnal awakenings, 3. 3 Need for rescue medication more than twice a week, 3. 4 One or more activity limitations4. Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc…Inclusion Criteria for COPD patients:Male, female, ≥40 years oldBeing able to provide written informed consent before the study.Patient with COPD stage A, B, C or D in stable condition with no exacerbations in the past 4 weeks.Patient followed for at least a year and mastering the technique of using devices i.e. aerosols, nebulizer etc…Inclusion Criteria for long covid patients:Male, female, aged ≥19.Being able to provide written informed consent before the study.Patients followed for respiratory symptoms linked to long Covid (symptoms for more than 12 weeks).Exclusion Criteria :Patient with severe asthma (for asthma groupe only)Prior use of Respicure®.Concomitant use with the following products: cytochrome P450 3A4 substrate drugs (e.g. statin, antifungals and fexofenadine), antibiotics (quinolones), immunosuppressants (cyclosporine) and glycoprotein P substrate drugs, e.g. antifungal and antiarrhythmic .Hypersensitivity to any of the ingredients.Hypersensitivity to peanuts.Concomitant intake of a product containing one or both of the active ingredients (resveratrol/quercetine).Pregnancy/ lactation.People who need to undergo surgery.Participation in another clinical study within the previous 30 days.Patient with asthma-COPD overlap syndrome or any other respiratory disease such as pneumonia, tuberculosis, pulmonary embolism, etc.Hormone-sensitive conditions such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids.Patients requiring admission to intensive care and/or requiring respiratory assistance.Patients requiring anticoagulant treatment at curative doses.